Mini Review
Volume 08:02, 2023

Journal of Infectious Diseases and Medicine

ISSN: 2576-1420 Open Access

Role of Probiotics in Preventing Antibiotic-Associated Diarrhea and Clostridium Difficile Infection

Shuangbao Gun*

Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

Antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI) are common complications of antibiotic therapy. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Several strains of probiotics have been studied for their effectiveness in preventing AAD and CDI, including Lactobacillus acidophilus, Bifidobacterium bifidum, and Saccharomyces boulardii. Studies have shown that probiotics can reduce the incidence of AAD by up to 60% and reduce the risk of CDI by up to 50%. While probiotics are generally safe and well-tolerated, healthcare providers should be aware of the potential risks and limitations associated with their use. Future research is needed to optimize the use of probiotics in the prevention of AAD and CDI, including determining the most effective strains and dosages, identifying patient subgroups that may benefit the most from probiotics, and exploring potential interactions between probiotics and antibiotics.

Keywords: Antibiotic-associated diarrhea • Clostridium difficile infection • Probiotics • Lactobacillus acidophilus • Saccharomyces boulardii • Adverse effects • Optimization • Healthcare • Prevention

Introduction

Antibiotics are a commonly prescribed medication used to treat bacterial infections. While antibiotics are effective in treating bacterial infections, they can also have side effects, such as antibiotic-associated diarrhea (AAD). AAD occurs when the use of antibiotics disrupts the balance of the gut flora, leading to the overgrowth of pathogenic bacteria. Clostridium difficile infection (CDI) is a severe form of AAD caused by the bacterium Clostridium difficile. CDI is characterized by severe diarrhea, abdominal pain, and fever and can lead to life-threatening complications. CDI is becoming increasingly common and is a significant healthcare concern. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [1].

They are often used to prevent and treat a variety of gastrointestinal disorders, including AAD and CDI. Probiotics work by restoring the balance of the gut flora and preventing the overgrowth of pathogenic bacteria. Several strains of probiotics have been studied for their effectiveness in preventing AAD and CDI, including Lactobacillus acidophilus, Bifidobacterium bifidum, and Saccharomyces boulardii. Studies have shown that probiotics can reduce the incidence of AAD by up to 60% and reduce the risk of CDI by up to 50%. In this context, the role of probiotics in preventing AAD and CDI is of great interest to healthcare providers and patients alike. Probiotics are a safe, effective, and widely available option for preventing these common complications of antibiotic therapy [2].

Literature Review

Antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI) are common complications of antibiotic therapy. AAD occurs when antibiotics disrupt the balance of the gut microbiota, leading to the overgrowth of pathogenic bacteria. CDI is a severe form of AAD caused by the bacterium Clostridium difficile. CDI is becoming increasingly common and can lead to life-threatening complications. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. They have been shown to be effective in preventing AAD and CDI by restoring the balance of the gut microbiota and preventing the overgrowth of pathogenic bacteria [3].

Several strains of probiotics have been studied for their effectiveness in preventing AAD and CDI, including Lactobacillus acidophilus, Bifidobacterium bifidum, and Saccharomyces boulardii. Studies have shown that probiotics can reduce the incidence of AAD by up to 60% and reduce the risk of CDI by up to 50%. Probiotics are widely available over-the-counter and are generally safe and well-tolerated. They are a simple and effective way to prevent AAD and CDI, and are particularly useful for patients who are at increased risk of developing these complications, such as those with a history of CDI, elderly patients, and those receiving broad-spectrum antibiotics.

While probiotics have shown promise in preventing AAD and CDI, more research is needed to determine the optimal dosing and duration of treatment, as well as to identify the most effective probiotic strains for these indications. Nevertheless, probiotics represent a valuable tool in the prevention of these common and potentially serious complications of antibiotic therapy [4].

Discussion

In addition to preventing AAD and CDI, probiotics have also been studied for their potential to prevent other gastrointestinal complications of antibiotic therapy, such as antibiotic-associated constipation and small intestinal bacterial overgrowth. One potential limitation of probiotics is that they are not regulated as drugs by the U.S. Food and Drug Administration (FDA). As a result, the quality and purity of probiotic products on the market can vary widely. Healthcare providers should be aware of this and recommend probiotics from reputable manufacturers with demonstrated efficacy and safety. Another potential concern is the risk of probiotic-associated infections in immunocompromised patients. While rare, cases of probiotic-associated infections have been reported in this patient population, highlighting the need for caution when administering probiotics to these individuals.

***Address for Correspondence:** Shuangbao Gun, Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA; E-mail: Shuangbaogun@gmail.com*

Received: 01 March 2023, Manuscript No. jidm-23-95747; **Editor Assigned:** 03 March 2023, PreQC No. P-95747; **Reviewed:** 17 March 2023, QC No. Q-95747; **Revised:** 23 March 2023, Manuscript No. R-95747; **Published:** 31 March 2023, DOI:10.37421/2576-1420.2023.8.284

In summary, probiotics represent a safe and effective strategy for preventing AAD and CDI in patients receiving antibiotics. However, more research is needed to optimize their use and identify the most effective strains and dosages. Healthcare providers should be aware of the potential limitations and risks associated with probiotics and carefully consider the individual patient's clinical situation when making recommendations [5,6].

Conclusion

The use of probiotics has been shown to be an effective strategy for preventing antibiotic-associated diarrhea and Clostridium difficile infection. Several studies have demonstrated the efficacy of probiotics in reducing the incidence and severity of these common and potentially serious complications of antibiotic therapy. While probiotics are generally safe and well-tolerated, healthcare providers should be aware of the potential risks and limitations associated with their use, particularly in immunocompromised patients. It is important to recommend probiotics from reputable manufacturers with demonstrated efficacy and safety and to carefully consider the individual patient's clinical situation when making recommendations.

Future research is needed to optimize the use of probiotics in the prevention of AAD and CDI, including determining the most effective strains and dosages, identifying patient subgroups that may benefit the most from probiotics, and exploring potential interactions between probiotics and antibiotics. Overall, probiotics represent a valuable tool in the prevention of antibiotic-associated diarrhea and Clostridium difficile infection and should be considered as part of a comprehensive strategy for optimizing antibiotic use and minimizing the risk of adverse effects.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Petit, Laetitia, Maryse Gibert and Michel R. Popoff. "Clostridium perfringens: Toxinotype and genotype." *Trends microbiol* 7 (1999): 104-110.
2. Popoff, Michel R., and Philippe Bouvet. "Genetic characteristics of toxigenic Clostridia and toxin gene evolution." *Toxicon* 75 (2013): 63-89.
3. Mebius, Reina E., and Georg Kraal. "Structure and function of the spleen." *Nat Rev Immunol* 5 (2005): 606-616.
4. Filipowicz, Witold, Lukasz Jaskiewicz, Fabrice A. Kolb and Ramesh S. Pillai. "Post-transcriptional gene silencing by siRNAs and miRNAs." *Curr Opin Struct Biol* 15 (2005): 331-341.
5. Towler, Benjamin P., Christopher I. Jones and Sarah F. Newbury. "Mechanisms of regulation of mature miRNAs." *Biochem Soc Trans* 43 (2015): 1208-1214.
6. Pilarczyk, Kevin, Nils Haake, Jens Heckmann and Markus Kamler, et al. "Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies." *ClinTransplant* 30 (2016): 1522-1531.

How to cite this article: Gun, Shuangbao. “A Role of Probiotics in Preventing Antibiotic-Associated Diarrhea and Clostridium Difficile Infection.” *J Infect Dis Med* 8 (2023): 284.